» Articles » PMID: 19194884

Taurine Deficiency is a Cause of Vigabatrin-induced Retinal Phototoxicity

Overview
Journal Ann Neurol
Specialty Neurology
Date 2009 Feb 6
PMID 19194884
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Although vigabatrin irreversibly constricts the visual field, it remains a potent therapy for infantile spasms and a third-line drug for refractory epilepsies. In albino animals, this drug induces a reduction in retinal cell function, retinal disorganization, and cone photoreceptor damage. The objective of this study was to investigate the light dependence of the vigabatrin-elicited retinal toxicity and to screen for molecules preventing this secondary effect of vigabatrin.

Methods: Rats and mice were treated daily with 40 and 3mg vigabatrin, respectively. Retinal cell lesions were demonstrated by assessing cell function with electroretinogram measurements, and quantifying retinal disorganization, gliosis, and cone cell densities.

Results: Vigabatrin-elicited retinal lesions were prevented by maintaining animals in darkness during treatment. Different mechanisms including taurine deficiency were reported to produce such phototoxicity; we therefore measured amino acid plasma levels in vigabatrin-treated animals. Taurine levels were 67% lower in vigabatrin-treated animals than in control animals. Taurine supplementation reduced all components of retinal lesions in both rats and mice. Among six vigabatrin-treated infants, the taurine plasma level was found to be below normal in three patients and undetectable in two patients.

Interpretation: These results indicate that vigabatrin generates a taurine deficiency responsible for its retinal phototoxicity. Future studies will investigate whether cotreatment with taurine and vigabatrin can limit epileptic seizures without inducing the constriction of the visual field. Patients taking vigabatrin could gain immediate benefit from reduced light exposures and dietetic advice on taurine-rich foods.

Citing Articles

Sustained Inhibition of GABA-AT by OV329 Enhances Neuronal Inhibition and Prevents Development of Benzodiazepine Refractory Seizures.

Colmers P, Arshad M, Mukherjee J, Lin S, Ng S, Sarmiere P eNeuro. 2024; 11(7).

PMID: 38937107 PMC: 11236575. DOI: 10.1523/ENEURO.0137-24.2024.


Pyroglutamate acidosis 2023. A review of 100 cases.

Stewart G Clin Med (Lond). 2024; 24(2):100030.

PMID: 38431210 PMC: 11091441. DOI: 10.1016/j.clinme.2024.100030.


Taurine: a promising nutraceutic in the prevention of retinal degeneration.

Garcia-Ayuso D, Di Pierdomenico J, Martinez-Vacas A, Vidal-Sanz M, Picaud S, Villegas-Perez M Neural Regen Res. 2023; 19(3):606-610.

PMID: 37721291 PMC: 10581579. DOI: 10.4103/1673-5374.380820.


Treatment-Resistant Epilepsy and Tuberous Sclerosis Complex: Treatment, Maintenance, and Future Directions.

Singh A, Hadjinicolaou A, Peters J, Salussolia C Neuropsychiatr Dis Treat. 2023; 19:733-748.

PMID: 37041855 PMC: 10083014. DOI: 10.2147/NDT.S347327.


Taurine: an essential amino sulfonic acid for retinal health.

Di Pierdomenico J, Martinez-Vacas A, Picaud S, Villegas-Perez M, Garcia-Ayuso D Neural Regen Res. 2022; 18(4):807-808.

PMID: 36204845 PMC: 9700098. DOI: 10.4103/1673-5374.353491.


References
1.
Cocker S, Lake N . Effects of dark maintenance on retinal biochemistry and function during taurine depletion in the adult rat. Vis Neurosci. 1989; 3(1):33-8. DOI: 10.1017/s0952523800012487. View

2.
Halonen T, Lehtinen M, Pitkanen A, Ylinen A, Riekkinen P . Inhibitory and excitatory amino acids in CSF of patients suffering from complex partial seizures during chronic treatment with gamma-vinyl GABA (vigabatrin). Epilepsy Res. 1988; 2(4):246-52. DOI: 10.1016/0920-1211(88)90015-0. View

3.
Izumi Y, Ishikawa M, Benz A, Izumi M, Zorumski C, Thio L . Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. Epilepsia. 2004; 45(9):1043-8. DOI: 10.1111/j.0013-9580.2004.01004.x. View

4.
Krauss G, Johnson M, Miller N . Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology. 1998; 50(3):614-8. DOI: 10.1212/wnl.50.3.614. View

5.
Buncic J, Westall C, Panton C, Munn J, MacKeen L, Logan W . Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology. 2004; 111(10):1935-42. PMC: 3880364. DOI: 10.1016/j.ophtha.2004.03.036. View